Project Grant R01AR084430
Award Date
7/15/25
Completion Date
6/30/30
Dollars Obligated
$691K
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
Salt Lake City, UT 84112, USA
Similar Awards
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) provides $219,605 to the Regents of the University of Michigan to conduct research on the role of the PIEZO1 ion channel in the development of post-traumatic osteoarthritis (PTOA). The research aims to 1) characterize the bi-directional regulation between PIEZO1 mechanotransduction and canonical Wnt/β-catenin signaling in...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will support research into the molecular regulatory mechanisms of a cartilage-enriched G protein-coupled receptor (GPCR) named ADGRG6 in maintaining joint homeostasis and preventing osteoarthritis (OA). The $426,889 award, effective from April 10, 2025 to March 31, 2030, will enable the University...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is funding research to investigate the mechanistic links between gait biomechanics and the development of knee osteoarthritis (KOA). The $644,152 award, which runs from January 2025 to December 2029, will be used by the University of North Carolina at Chapel Hill to: 1) determine the acute in vivo...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $1,066,302 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Massachusetts Medical School. The grant, effective April 1, 2025 through March 31, 2029, will fund the creation of a biomedical knowledgebase to promote and facilitate the use of the Osteoarthritis Initiative (OAI), a rich 16-year observational study with comprehensive...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $618,629 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to The Regents of the University of Colorado to establish a new "microphysiological joint-on-chip" system. The objective is to create a realistic human joint model that can support mechanistic study of arthritic diseases and rapid testing of candidate treatments. The researchers plan to develop...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), will provide $196,460 to the University of Pittsburgh to test a novel microphysiological system as a tool to study neuroimmune interactions in osteoarthritis pain. The goal is to use this system, which includes cartilage, synovial-like, and innervated tissue, to investigate the influence...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $206,023 Project Grant (CFDA 93.846 - Arthritis, Musculoskeletal and Skin Diseases Research) to Cornell University to investigate mechanotransduction pathways in injured cartilage. The project aims to determine how local peak strain magnitude and manipulation of calcium-dependent signaling or mitochondrial bioenergetics affect the distribution of chondrocyte phenotypes after impact injury, using a novel...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $456,808 to the Buck Institute for Research on Aging to develop innovative mass spectrometry imaging (MSI) technologies and perform deep proteomic profiling of bone tissues. The goal is to spatially visualize changes in the extracellular matrix and glycans related to osteoarthritis,...
This $578,944 federal Project Grant award was provided by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The primary objective is to decipher the genetics of osteoarthritis (OA) susceptibility, heterogeneity, and progression. The research aims to identify new and fine-map known genetic loci associated with OA and total joint replacement, disentangle OA heterogeneity by...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $123,040 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to the University of Kansas Medical Center Research Institute, Inc. (KUMCRI) to investigate the therapeutic role of the NFAT1 transcription factor in osteoarthritis. The 5-year project, which began on August 1, 2024, aims to evaluate the potential of AAV-delivered NFAT1 gene therapy in treating...